The long-term implications of p38 inhibitors on COPD progression and mortality remain uncertain since most clinical trials have focused primarily on short-term assessments of lung function and symptomatology [16, 174]. This evidence concerns the gene MAPK14 and chronic obstructive pulmonary disease.